GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Scienture Holdings Inc (NAS:SCNX) » Definitions » Net Current Asset Value

SCNX (Scienture Holdings) Net Current Asset Value : $-2.23 (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Scienture Holdings Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Scienture Holdings's net current asset value per share for the quarter that ended in Dec. 2024 was $-2.23.

The historical rank and industry rank for Scienture Holdings's Net Current Asset Value or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Scienture Holdings was 122.73. The lowest was 5.29. And the median was 13.15.

SCNX's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 5.485
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Scienture Holdings Net Current Asset Value Historical Data

The historical data trend for Scienture Holdings's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scienture Holdings Net Current Asset Value Chart

Scienture Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.01 4.37 -1.36 -10.21 -2.23

Scienture Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.21 7.76 6.46 -0.22 -2.23

Competitive Comparison of Scienture Holdings's Net Current Asset Value

For the Pharmaceutical Retailers subindustry, Scienture Holdings's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scienture Holdings's Price-to-Net-Current-Asset-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Scienture Holdings's Price-to-Net-Current-Asset-Value falls into.


;
;

Scienture Holdings Net Current Asset Value Calculation

Scienture Holdings's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(6.305-25.782-0-0)/8.751
=-2.23

Scienture Holdings's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(6.305-25.782-0-0)/8.751
=-2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scienture Holdings  (NAS:SCNX) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Scienture Holdings Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Scienture Holdings's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Scienture Holdings Business Description

Traded in Other Exchanges
Address
2420 Brunello Trace, Lutz, FL, USA, 33558
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
Executives
A. Jeffrey Newell director 645 CAMP DIXIE RD, PASCOAG RI 02859
Donald G. Fell director 17537 DARBY LANE, LUTZ FL 33558
Janet Huffman officer: CFO, PAO, PFO 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Michael L Peterson director 17 CANARY COURT, DANVILLE CA 94526
Christine L. Jennings director 3840 LAND O' LAKES BLVD., LAND O' LAKES FL 34639
Prashant Patel director, 10 percent owner, officer: President 17537 DARBY LANE, LUTZ FL 33558
Pamela Tenaerts director PO BOX 15012, SARASOTA FL 34277
Gary Augusta director 700 NORTH BRAND BLVD., SUITE 1400, GLENDALE CA 91203
Howard A. Doss officer: CFO 17537 DARBY LANE, LUTZ FL 90067
Surendra K Ajjarapu director, 10 percent owner, officer: CEO 8604 BUTTON BUSH CT, TAMPA FL 33647
Donald V. Almeida director 1115 GUNN HIGHWAY, SUITE 202, ODESSA FL 33556
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Sandhya Ajjarapu 10 percent owner 17537 DARBY LANE, LUTZ FL 33558